Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07724106RecruitingPhase 1
NeoOVSV vaccine for ovarian cancer after surgery
This trial tests a personalized vaccine made from your own tumor tissue called NeoOVSV. It is meant to train your immune system to fight any remaining cancer after surgery. The vaccine is a personal treatment because it uses your tumor's unique markers.
Chengdu, SichuanAges 18–75 - NCT07811037RecruitingPhase 1/Phase 2
Safety and effect of SGT003 for advanced solid tumors
This trial tests a new experimental medicine called SGT003 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the medicine is safe, how the body handles it, and whether it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07777484RecruitingPhase 1
Study of TRB-001 vaccine for Parkinson's disease after prior immunotherapy
This study tests an experimental vaccine called TRB-001 in people with Parkinson's disease who have already received a previous immunotherapy targeting alpha-synuclein. The goal is to see if the vaccine is safe and how it affects the immune system and the disease.
ViennaAges 18 years+ - NCT07694557RecruitingPhase 1
Safety and immune response study of YKYY025 RSV vaccine
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Anning, YunnanAges 18 years+ - NCT07557420RecruitingPhase 3
Ravulizumab for Neuromyelitis Optica Spectrum Disorder in Chinese Adults
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
BeijingAges 18–130 - NCT07833436RecruitingPhase 1
Testing a new Lassa fever vaccine
This trial tests a new vaccine against Lassa fever to see if it is safe and how well it triggers an immune response. It may help protect against this serious infection.
ParisAges 18–55 - NCT07779408RecruitingPhase 1/Phase 2
H5N8 flu vaccine study for healthy adults
This study tests an experimental flu vaccine designed to protect against the H5N8 bird flu virus. It is given with an ingredient that may boost the immune response. The study will check if the vaccine is safe and how well it triggers the body's defenses.
Tempe, ArizonaAges 18 years+ - NCT07565090RecruitingPhase 1
Sudan Virus Vaccine Safety Study for Healthy Adults
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
Washington D.C., District of ColumbiaAges 18–50 - NCT07710872RecruitingPhase 3
Meningitis vaccine study for infants and toddlers
This study tests an experimental vaccine to protect babies and toddlers from meningitis (a serious infection of the brain and spinal cord). It checks how well the vaccine works and how safe it is in young children.
JingxiAges 2 months–1.9 years - NCT07615985RecruitingPhase 1
Safety and Blood Levels of PMG1016 in Healthy Adults
This study tests a new experimental medicine called PMG1016 to see how safe it is and how it moves through the body in healthy volunteers. You'll receive a single dose and have your blood checked and heart monitored to make sure the medicine is well-tolerated.
Brisbane, QueenslandAges 18–55 - NCT07758972RecruitingPhase 1
Gonorrhea vaccine safety study
This trial tests a new vaccine designed to protect against gonorrhea, a common sexually transmitted infection. The study checks how safe the vaccine is and how well it trains the immune system to fight the bacteria.
Neu-Ulm, BavariaAges 18–50 - NCT07477587RecruitingPhase 1
Comparing two myeloma treatments for new patients
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
Springdale, ArkansasAges 18 years+ - NCT07780383RecruitingPhase 1
Single-dose study for healthy adults and early Alzheimer's participants
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
Anaheim, CaliforniaAges 18–80 - NCT07840027RecruitingPhase 1
Vaccine for early Parkinson's disease
This study tests a new investigational vaccine called TRB-001 for people with early Parkinson's disease. It looks at whether the vaccine is safe and whether it can help the immune system fight the disease.
ViennaAges 40–75 - NCT07653100RecruitingPhase 3
RSV vaccine study for adults with chronic conditions
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Visakhapatnam, Andhra PradeshAges 18 years+ - NCT07476326RecruitingPhase 1
Comparing a new biosimilar to Opdivo for melanoma after surgery
This trial tests whether a new biosimilar drug (Bmab1700) works as well as the approved immunotherapy Opdivo (nivolumab) to prevent melanoma from coming back after surgery. You would receive either the biosimilar or Opdivo for about a year, and researchers will compare how your body handles the drug and its safety.
Bento GonçalvesAges 18 years+ - NCT07536308RecruitingPhase 1
Nasal COVID-19 booster vaccine safety trial
This trial tests a new nasal spray COVID-19 booster vaccine. It aims to see if the vaccine is safe and produces a strong immune response when given through the nose and inhaled, in people who have already been vaccinated.
Decatur, GeorgiaAges 18–64 - NCT07726147RecruitingPhase 1
Testing a new allergy shot for Japanese cedar pollen
This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.
Tokyo, Shinjuku-kuAges 18–65 - NCT07802964RecruitingPhase 1
Early study of HRS-4139 in healthy adults
This trial studies an investigational medicine called HRS-4139 in healthy adults. The purpose is to see how safe it is, how the body processes it, and how it affects the immune system.
Changsha, HunanAges 18–55 - NCT07688369RecruitingPhase 1
Testing a new polio vaccine in healthy adults
This trial tests a new recombinant polio vaccine (rPV) to see if it is safe and works as well as the current IPOL vaccine. It is for healthy adults who have not had polio or a polio vaccine recently.
East Melbourne, VictoriaAges 18–60 - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT07769983Enrolling by invitationPhase 1
HIV vaccine study for people on effective treatment
This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.
Bern, Canton of BernAges 18 years+ - NCT07520214Enrolling by invitationEarly Phase 1
Cancer vaccine to prevent glioblastoma recurrence
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07509047RecruitingPhase 2
Cholera vaccine safety study for adults and children
This trial tests a new cholera vaccine in healthy people ages 1 to 45. It aims to see if the vaccine is safe and creates a good immune response.
Nairobi, Kenyatta National Hospital ComplexAges 1–45
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 146 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.